AMV 564

Drug Profile

AMV 564

Alternative Names: AMV564; T-564

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Affimed Therapeutics
  • Developer Amphivena Therapeutics
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; CD33 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia
  • Preclinical Myelodysplastic syndromes

Most Recent Events

  • 09 Dec 2017 Preclinical trials in Myelodysplastic syndromes in USA (Parenteral) before December 2017
  • 09 Dec 2017 Pharmacodynamics data from preclinical studies in Myelodysplastic syndromes released by Amphivena Therapeutics
  • 29 Nov 2017 AMV 564 receives Orphan Drug status for Acute myeloid leukaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top